Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00275431 · ClinicalTrials.gov registry record · Phase 2
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
A Phase 2 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by Ascenta Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT00275431: Completed Phase 2 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, sponsored by Ascenta Therapeutics.
NCT00275431 is a Phase 2 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma that has completed, run by Ascenta Therapeutics. The registered enrollment target is 50 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00275431, a Phase 2 study of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma, has completed, sponsored by Ascenta Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
Conditions Studied
Interventions
- DRUG AT-101
Study Locations (11)
New York
- - New York
- - Rochester
Alabama
- - Birmingham
California
- - San Diego
Georgia
- - Atlanta
Illinois
- - Chicago
Massachusetts
- - Boston
North Carolina
- - High Point
South Carolina
- - Hilton Head Island
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
What the finished NCT00275431 record still lists
NCT00275431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower).
The record links to 5 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which AT-101 is the first listed.
NCT00275431 lists 11 locations in 10 states (New York, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT00275431 about?
NCT00275431 is a clinical study titled "Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies". This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
What is the current status of trial NCT00275431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-11. Estimated completion is 2008-12.
What conditions does trial NCT00275431 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Diffuse Large Cell Lymphoma.
What interventions are being tested in trial NCT00275431?
The interventions under investigation include: AT-101 (DRUG).
Who is sponsoring clinical trial NCT00275431?
This trial is sponsored by Ascenta Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00275431 being conducted?
This trial has 11 study locations across Alabama, California, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00275431's enrollment target sits among peer trials
50 101st of 187 higher than 83 of 187 other Chronic Lymphocytic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RECRUITING · Phase 2
-
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
RECRUITING · Phase 2
-
Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia With History of Non-melanoma Skin Cancers
RECRUITING · Phase 2
-
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
RECRUITING · Phase 2
-
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia